L-3,4-dihydroxyphenylalanine (L-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease

Jessica L Billings; Sarah L Gordon; Tristan Rawling; Philip A Doble; Ashley I Bush; Paul A Adlard; David I Finkelstein; Dominic J Hare

Journal article

L-3,4-dihydroxyphenylalanine (L-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease

Jessica L Billings, Sarah L Gordon, Tristan Rawling, Philip A Doble, Ashley I Bush, Paul A Adlard, David I Finkelstein, Dominic J Hare

Journal of Neurochemistry | WILEY | Published : 2019

DOI: 10.1111/jnc.14676

University of Melbourne Researchers

Sarah Gordon Author Florey Department of Neuroscience and Mental Health

Ashley Bush Author Florey Department of Neuroscience and Mental Health

David Finkelstein Author Florey Department of Neuroscience and Mental Health

Paul Adlard Author Florey Department of Neuroscience and Mental Health

Related Projects (5)

IRON EXPORT PROTEIN FAILURE IN PARKINSONISM AND DEMENTIA

We recently discovered a novel relationship between the Alzheimer’s amyloid precursor protein (APP) and tau, and that both proteins play a r..

Identifying the mechanisms of action of a novel 8-hydroxy quinazolinone in models of Parkinson's disease

By the time symptoms of Parkinson's disease (PD) appear, 60-70% of the cells in a crucial part of the brain called the substantia nigra have..

The role of the disease-related proteins APP and Tau in iron content within the brain

We have recently discovered a novel relationship between amyloid precursor protein (APP) and tau in regulating neuronal iron balance. This p..

THE FUNCTIONAL INTERPLAY BETWEEN ALPHA SYNUCLEIN AND SYNAPTOPHYSIN IN SYNAPTIC VESICLE RECYCLING

Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, affecting 7 million people worldwide. ?-synuclein is a protei..

Developing a novel therapy for Parkinson's Disease

By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a large proportion (60-70%) of the cells in a speci..

Grants

Awarded by ESI Ltd

Awarded by Australian Research Council

Awarded by National Health and Medical Research Council

Funding Acknowledgements

We thank Professor Virginia Lee for providing the original hA53T mouse line from which animals in this report were descendants. We also thank Ms Milawaty Nurjono for assistance with animal culling. The Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. P.A.D and D.J.H. are supported by funds from the Australian Research Council Linkage Project scheme in partnership with Agilent Technologies and ESI Ltd (LP120200081). P.A.A. received a Future Fellowship from the Australian Research Council (FT120100030). The National Health and Medical Research Council supported this work with funds to S.L.G. (Career Development Fellowship 1085483), A.I.B. (Program Grant 1132604; Research Fellowship 1103703), P.A.A. (Project Grant 1025774), D.I.F. (Project Grants 1061761, 1044542, 1043992 and 509286) and D.J.H. (Career Development Fellowship in partnership with Agilent Technologies 1122981). D.I.F. also receives support from the Michael J. Fox Foundation for Parkinson's Research. P.A.A. and D.I.F. are paid consultants to and shareholders in Prana Biotechnology Ltd. A.I.B. is a shareholder in Prana Biotechnology Ltd., Mesoblast Pty Ltd., Cogstate Pty Ltd., NextVet Ltd., Collaborative Medicinal Development Pty Ltd., and a payed consultant for Collaborative Medicinal Development Pty Ltd. P.A.D. and D.J.H. receive material and research support from Agilent Technologies and ESI Ltd.